The global Benign Prostatic Hyperplasia (BPH) Drugs market is projected to grow from US$ 3452.6 million in 2024 to US$ 4195.1 million by 2030, at a Compound Annual Growth Rate (CAGR) of 3.3% during the forecast period.

Benign Prostatic Hyperplasia (BPH) Drugs Market

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

Report Covers:

This report presents an overview of global market for Benign Prostatic Hyperplasia (BPH) Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Benign Prostatic Hyperplasia (BPH) Drugs, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Benign Prostatic Hyperplasia (BPH) Drugs, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Benign Prostatic Hyperplasia (BPH) Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Benign Prostatic Hyperplasia (BPH) Drugs sales, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Benign Prostatic Hyperplasia (BPH) Drugs Market Report

Report Metric	Details
Report Name	Benign Prostatic Hyperplasia (BPH) Drugs Market
Accounted market size in 2024	US$ 3452.6 million
Forecasted market size in 2030	US$ 4195.1 million
CAGR	3.3
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	Alpha-Blocker Phosphodiesterase Type-5 Inhibitors Others
Segment by Application	Hospitals Drugstores Others
Segment by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA, Mylan, Novartis, Merck
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Benign Prostatic Hyperplasia (BPH) Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

FAQ for this report

How fast is Benign Prostatic Hyperplasia (BPH) Drugs Market growing?

Ans: The Benign Prostatic Hyperplasia (BPH) Drugs Market witnessing a CAGR of 3.3 during the forecast period 2024-2030.

What is the Benign Prostatic Hyperplasia (BPH) Drugs Market size in 2030?

Ans: The Benign Prostatic Hyperplasia (BPH) Drugs Market size in 2030 will be US$ 4195.1 million.

What is the Benign Prostatic Hyperplasia (BPH) Drugs Market share by region?

Ans: Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%.

Who are the main players in the Benign Prostatic Hyperplasia (BPH) Drugs Market report?

Ans: The main players in the Benign Prostatic Hyperplasia (BPH) Drugs Market are Astellas Pharma, Sanofi, Pfizer, Abbott, Allergan, TEVA, Mylan, Novartis, Merck

What are the Application segmentation covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report?

Ans: The Applications covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report are Hospitals, Drugstores, Others

What are the Type segmentation covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report?

Ans: The Types covered in the Benign Prostatic Hyperplasia (BPH) Drugs Market report are Alpha-Blocker, Phosphodiesterase Type-5 Inhibitors, Others

1 Study Coverage

1.1 Benign Prostatic Hyperplasia (BPH) Drugs Product Introduction

1.2 Market by Type

1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Alpha-Blocker

1.2.3 Phosphodiesterase Type-5 Inhibitors

1.2.4 Others

1.3 Market by Application

1.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Drugstores

1.3.4 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts 2019-2030

2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region

2.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019 VS 2023 VS 2030

2.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024)

2.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030)

2.2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2030)

2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Estimates and Forecasts 2019-2030

2.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region

2.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2019 VS 2023 VS 2030

2.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024)

2.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030)

2.4.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2030)

2.5 US & Canada

2.6 Europe

2.7 China

2.8 Asia (excluding China)

2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers

3.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2019-2024)

3.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturers (2019-2024)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs in 2023

3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers

3.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2019-2024)

3.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturers (2019-2024)

3.2.3 Global Top 10 and Top 5 Companies by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2023

3.3 Global Key Players of Benign Prostatic Hyperplasia (BPH) Drugs, Industry Ranking, 2022 VS 2023 VS 2024

3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Price by Manufacturers

3.5 Analysis of Competitive Landscape

3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Base Distribution and Headquarters

3.7 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Offered and Application

3.8 Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry

3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type

4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Sales by Type (2019-2024)

4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Type (2025-2030)

4.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type

4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Revenue by Type (2019-2024)

4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Revenue by Type (2025-2030)

4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type

4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2024)

4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2025-2030)

5 Market Size by Application

5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application

5.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Sales by Application (2019-2024)

5.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Sales by Application (2025-2030)

5.1.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application

5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Historical Revenue by Application (2019-2024)

5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Forecasted Revenue by Application (2025-2030)

5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application

5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2024)

5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2025-2030)

6 US & Canada

6.1 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type

6.1.1 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)

6.1.2 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)

6.2 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application

6.2.1 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)

6.2.2 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)

6.3 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country

6.3.1 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030

6.3.2 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)

6.3.3 US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)

6.3.4 US

6.3.5 Canada

7 Europe

7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type

7.1.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)

7.1.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)

7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application

7.2.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)

7.2.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)

7.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country

7.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030

7.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)

7.3.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)

7.3.4 Germany

7.3.5 France

7.3.6 U.K.

7.3.7 Italy

7.3.8 Russia

8 China

8.1 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size

8.1.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales (2019-2030)

8.1.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030)

8.2 China Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application

8.2.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)

8.2.2 China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type

9.1.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)

9.1.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)

9.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application

9.2.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)

9.2.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)

9.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region

9.3.1 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region: 2019 VS 2023 VS 2030

9.3.2 Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2030)

9.3.3 Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2030)

9.3.4 Japan

9.3.5 South Korea

9.3.6 China Taiwan

9.3.7 Southeast Asia

9.3.8 India

10 Middle East, Africa and Latin America

10.1 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Type

10.1.1 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2030)

10.1.2 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2030)

10.2 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Application

10.2.1 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2030)

10.2.2 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2030)

10.3 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country

10.3.1 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country: 2019 VS 2023 VS 2030

10.3.2 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2030)

10.3.3 Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2030)

10.3.4 Brazil

10.3.5 Mexico

10.3.6 Turkey

10.3.7 Israel

10.3.8 GCC Countries

11 Company Profiles

11.1 Eli Lilly

11.1.1 Eli Lilly Company Information

11.1.2 Eli Lilly Overview

11.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Eli Lilly Recent Developments

11.2 GlaxoSmithKline

11.2.1 GlaxoSmithKline Company Information

11.2.2 GlaxoSmithKline Overview

11.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 GlaxoSmithKline Recent Developments

11.3 Astellas Pharma

11.3.1 Astellas Pharma Company Information

11.3.2 Astellas Pharma Overview

11.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 Astellas Pharma Recent Developments

11.4 Sanofi

11.4.1 Sanofi Company Information

11.4.2 Sanofi Overview

11.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Sanofi Recent Developments

11.5 Pfizer

11.5.1 Pfizer Company Information

11.5.2 Pfizer Overview

11.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Pfizer Recent Developments

11.6 Abbott

11.6.1 Abbott Company Information

11.6.2 Abbott Overview

11.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Abbott Recent Developments

11.7 Allergan

11.7.1 Allergan Company Information

11.7.2 Allergan Overview

11.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Allergan Recent Developments

11.8 TEVA

11.8.1 TEVA Company Information

11.8.2 TEVA Overview

11.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 TEVA Recent Developments

11.9 Mylan

11.9.1 Mylan Company Information

11.9.2 Mylan Overview

11.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 Mylan Recent Developments

11.10 Novartis

11.10.1 Novartis Company Information

11.10.2 Novartis Overview

11.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.10.5 Novartis Recent Developments

11.11 Merck

11.11.1 Merck Company Information

11.11.2 Merck Overview

11.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue and Gross Margin (2019-2024)

11.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

11.11.5 Merck Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Chain Analysis

12.2 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Mode & Process

12.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales and Marketing

12.4.1 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels

12.4.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors

12.5 Benign Prostatic Hyperplasia (BPH) Drugs Customers

13 Market Dynamics

13.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends

13.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers

13.3 Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges

13.4 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

14 Key Findings in The Global Benign Prostatic Hyperplasia (BPH) Drugs Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Table 2. Major Manufacturers of Alpha-Blocker

Table 3. Major Manufacturers of Phosphodiesterase Type-5 Inhibitors

Table 4. Major Manufacturers of Others

Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2024)

Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2025-2030)

Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)

Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)

Table 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2024)

Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2025-2030)

Table 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturers (2019-2024) & (M Units)

Table 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Manufacturers (2019-2024)

Table 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturers (2019-2024) & (US$ Million)

Table 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Manufacturers (2019-2024)

Table 20. Global Key Players of Benign Prostatic Hyperplasia (BPH) Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 21. Benign Prostatic Hyperplasia (BPH) Drugs Price by Manufacturers 2019-2024 (US$/Unit)

Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Benign Prostatic Hyperplasia (BPH) Drugs as of 2023)

Table 24. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Manufacturing Base Distribution and Headquarters

Table 25. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Product Offered and Application

Table 26. Global Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, Date of Enter into This Industry

Table 27. Mergers & Acquisitions, Expansion Plans

Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)

Table 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2019-2024)

Table 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Type (2025-2030)

Table 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)

Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)

Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2019-2024)

Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Type (2025-2030)

Table 36. Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2019-2024) & (US$/Unit)

Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Type (2025-2030) & (US$/Unit)

Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)

Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2019-2024)

Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Application (2025-2030)

Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)

Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)

Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2019-2024)

Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Application (2025-2030)

Table 46. Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2019-2024) & (US$/Unit)

Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Price Forecast by Application (2025-2030) & (US$/Unit)

Table 48. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 49. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)

Table 50. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)

Table 51. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)

Table 52. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 53. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)

Table 54. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)

Table 55. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)

Table 56. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 57. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 58. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 59. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)

Table 60. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)

Table 61. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 62. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)

Table 63. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)

Table 64. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)

Table 65. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 66. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)

Table 67. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)

Table 68. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)

Table 69. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 70. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 71. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 72. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)

Table 73. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)

Table 74. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 75. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)

Table 76. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)

Table 77. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)

Table 78. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 79. China Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)

Table 80. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)

Table 81. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)

Table 82. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 83. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)

Table 84. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)

Table 85. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)

Table 86. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 87. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)

Table 88. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)

Table 89. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)

Table 90. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 91. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2019-2024) & (US$ Million)

Table 92. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2025-2030) & (US$ Million)

Table 93. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2019-2024) & (M Units)

Table 94. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2025-2030) & (M Units)

Table 95. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2019-2024) & (M Units)

Table 96. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2025-2030) & (M Units)

Table 97. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2019-2024) & (US$ Million)

Table 98. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2025-2030) & (US$ Million)

Table 99. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2019-2024) & (M Units)

Table 100. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2025-2030) & (M Units)

Table 101. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2019-2024) & (US$ Million)

Table 102. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2025-2030) & (US$ Million)

Table 103. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 104. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2019-2024) & (US$ Million)

Table 105. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2025-2030) & (US$ Million)

Table 106. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2019-2024) & (M Units)

Table 107. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2025-2030) & (M Units)

Table 108. Eli Lilly Company Information

Table 109. Eli Lilly Description and Major Businesses

Table 110. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 111. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 112. Eli Lilly Recent Developments

Table 113. GlaxoSmithKline Company Information

Table 114. GlaxoSmithKline Description and Major Businesses

Table 115. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 116. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 117. GlaxoSmithKline Recent Developments

Table 118. Astellas Pharma Company Information

Table 119. Astellas Pharma Description and Major Businesses

Table 120. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 121. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 122. Astellas Pharma Recent Developments

Table 123. Sanofi Company Information

Table 124. Sanofi Description and Major Businesses

Table 125. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 126. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 127. Sanofi Recent Developments

Table 128. Pfizer Company Information

Table 129. Pfizer Description and Major Businesses

Table 130. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 131. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 132. Pfizer Recent Developments

Table 133. Abbott Company Information

Table 134. Abbott Description and Major Businesses

Table 135. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 136. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 137. Abbott Recent Developments

Table 138. Allergan Company Information

Table 139. Allergan Description and Major Businesses

Table 140. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 141. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 142. Allergan Recent Developments

Table 143. TEVA Company Information

Table 144. TEVA Description and Major Businesses

Table 145. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 146. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 147. TEVA Recent Developments

Table 148. Mylan Company Information

Table 149. Mylan Description and Major Businesses

Table 150. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 151. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 152. Mylan Recent Developments

Table 153. Novartis Company Information

Table 154. Novartis Description and Major Businesses

Table 155. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 156. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 157. Novartis Recent Developments

Table 158. Merck Company Information

Table 159. Merck Description and Major Businesses

Table 160. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 161. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Model Numbers, Pictures, Descriptions and Specifications

Table 162. Merck Recent Developments

Table 163. Key Raw Materials Lists

Table 164. Raw Materials Key Suppliers Lists

Table 165. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List

Table 166. Benign Prostatic Hyperplasia (BPH) Drugs Customers List

Table 167. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends

Table 168. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers

Table 169. Benign Prostatic Hyperplasia (BPH) Drugs Market Challenges

Table 170. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints

Table 171. Research Programs/Design for This Report

Table 172. Key Data Information from Secondary Sources

Table 173. Key Data Information from Primary Sources

List of Figures

Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Picture

Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Type in 2023 & 2030

Figure 4. Alpha-Blocker Product Picture

Figure 5. Phosphodiesterase Type-5 Inhibitors Product Picture

Figure 6. Others Product Picture

Figure 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Application in 2023 & 2030

Figure 9. Hospitals

Figure 10. Drugstores

Figure 11. Others

Figure 12. Benign Prostatic Hyperplasia (BPH) Drugs Report Years Considered

Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue 2019-2030 (US$ Million)

Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2019-2030)

Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales 2019-2030 ((M Units)

Figure 18. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2019-2030)

Figure 19. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)

Figure 20. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY (2019-2030) & (US$ Million)

Figure 21. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)

Figure 22. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY (2019-2030) & (US$ Million)

Figure 23. China Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)

Figure 24. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY (2019-2030) & (US$ Million)

Figure 25. Asia (excluding China) Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)

Figure 26. Asia (excluding China) Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY (2019-2030) & (US$ Million)

Figure 27. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales YoY (2019-2030) & (M Units)

Figure 28. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue YoY (2019-2030) & (US$ Million)

Figure 29. The Benign Prostatic Hyperplasia (BPH) Drugs Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023

Figure 30. The Top 5 and 10 Largest Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs in the World: Market Share by Benign Prostatic Hyperplasia (BPH) Drugs Revenue in 2023

Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

Figure 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

Figure 36. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

Figure 37. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

Figure 38. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

Figure 39. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

Figure 40. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)

Figure 41. US & Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)

Figure 42. U.S. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 43. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 44. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

Figure 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

Figure 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

Figure 48. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)

Figure 49. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)

Figure 50. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 51. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 52. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 53. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 54. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 55. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

Figure 56. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

Figure 57. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

Figure 58. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

Figure 59. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

Figure 60. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

Figure 61. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

Figure 62. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

Figure 63. Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Region (2019-2030)

Figure 64. Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Region (2019-2030)

Figure 65. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 66. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 67. China Taiwan Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 68. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 69. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 70. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2019-2030)

Figure 71. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2019-2030)

Figure 72. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2019-2030)

Figure 73. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2019-2030)

Figure 74. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Country (2019-2030)

Figure 75. Middle East, Africa and Latin America Benign Prostatic Hyperplasia (BPH) Drugs Sales Share by Country (2019-2030)

Figure 76. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 77. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 78. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 79. Israel Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 80. GCC Countries Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2019-2030) & (US$ Million)

Figure 81. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain

Figure 82. Benign Prostatic Hyperplasia (BPH) Drugs Production Process

Figure 83. Channels of Distribution

Figure 84. Distributors Profiles

Figure 85. Bottom-up and Top-down Approaches for This Report

Figure 86. Data Triangulation

Figure 87. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions